Search Results - Yusri Elsayed

  • Showing 1 - 12 results of 12
Refine Results
  1. 1
    Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma

    Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma by Jean‐Yves Blay, Margaret von Mehren, Brian L. Samuels, Michael Fanucchi, Isabelle Ray‐Coquard, B. Buckley, Leen Gilles, Claudia Lebedinsky, Yusri Elsayed, Axel Le Cesne

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma

    Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma by Ram Pillarisetti, Danlin Yang, Jianhong Yao, Melissa Smith, Leopoldo Luistro, Peter Vulfson, James Testa, Kathryn Packman, Scott R. Brodeur, Ricardo M. Attar, Yusri Elsayed, Ulrike Philippar

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

    Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma by Kodandaram Pillarisetti, Gordon Powers, Leopoldo Luistro, Alexander Babich, Eric T. Baldwin, Yingzhe Li, Xiaochun Zhang, Mark Mendonça, Nate Majewski, Rupesh Nanjunda, Diana Chin, Kathryn Packman, Yusri Elsayed, Ricardo M. Attar, François Gaudet

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

    Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase... by Pier Luigi Zinzani, Nuriet K. Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie‐Lee Esseltine, Panteli Theocharous, Christopher Enny, Eugene Zhu, Yusri Elsayed, Bertrand Coiffier

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

    Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma by Qin Ryan, Donna Headlee, Milin Acharya, Alex Sparreboom, Jane B. Trepel, Ziyang Ye, William D. Figg, Kyunghwa Hwang, Eun Joo Chung, Anthony J. Murgo, Giovanni Melillo, Yusri Elsayed, Manish Monga, Mikhail Kalnitskiy, James A. Zwiebel, Edward A. Sausville

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

    Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma by Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Tineke Casneuf, Damien Fink, Xin Miao, Yang Chen, Tara Stephenson, Arnob Banerjee, Brandi Hilder, Jeffery S. Russell, Jeffrey R. Infante, Yusri Elsayed, Jennifer Smit, Jenna D. Goldberg

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

    A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advance... by Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, Steve Mcclue, Johan W. Smit, Ann Forslund, Charles E. Phelps, A. John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

    A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma by Kodandaram Pillarisetti, Suzanne C. Edavettal, Mark Mendonça, Yingzhe Li, Mark Tornetta, Alexander Babich, Nate Majewski, Matt Husovsky, Dara Reeves, Eileen S. Walsh, Diana Chin, Leopoldo Luistro, Jocelin Joseph, Gerald Chu, Kathryn Packman, Shoba Shetty, Yusri Elsayed, Ricardo M. Attar, François Gaudet

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia

    A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia by Priyanka Nair-Gupta, Michael Diem, Dara Reeves, Weirong Wang, Robert Schulingkamp, Katrin Sproesser, Bethany Mattson, Bradley Heidrich, Mark Mendonça, Jocelin Joseph, Jocelyn Sendecki, Brad Foulk, Gerald Chu, Damien Fink, Qun Jiao, Sheng‐Jiun Wu, Kathryn Packman, Yusri Elsayed, Ricardo M. Attar, François Gaudet

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

    Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial by Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiřı́ Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer Shpilberg, Dixie‐Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri Elsayed, Pier Luigi Zinzani

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

    Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomiz... by George D. Demetri, Sant P. Chawla, Margaret von Mehren, Paul S. Ritch, Laurence H. Baker, Jean‐Yves Blay, Kenneth R. Hande, Mary Lou Keohan, Brian L. Samuels, Scott M. Schuetze, Claudia Lebedinsky, Yusri Elsayed, Miguel Izquierdo, Javier Gómez‐Román, Youn C. Park, Axel Le Cesne

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

    International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) by Anas Younes, Patrick Hilden, Bertrand Coiffier, Anton Hagenbeek, Gilles Salles, Wyndham H. Wilson, John F. Seymour, Kara M. Kelly, John G. Gribben, M. Pfreunschuh, Franck Morschhauser, Heiko Schöder, Andrew D. Zelenetz, Jürgen Rademaker, Ranjana H. Advani, Nancy Valente, Catherine Fortpied, Thomas E. Witzig, Laurie H. Sehn, Andreas Engert, Richard I. Fisher, Pier Luigi Zinzani, Massimo Federico, Martin Hutchings, Catherine M. Bollard, Marek Trněný, Yusri Elsayed, Kensei Tobinai, Jeremy S. Abramson, Nathan Fowler, André Goy, Mitchell R. Smith, Stephen M. Ansell, John Kuruvilla, Martin Dreyling, Catherine Thiéblemont, Richard F. Little, Igor Aurer, Marinus H. J. van Oers, Kenichi Takeshita, Ajay K. Gopal, Simon Rule, Sven de Vos, Ioana Kloos, Mark Kaminski, Michel Meignan, Lawrence H. Schwartz, John P. Leonard, Stephen J. Schuster, Venkatraman Seshan

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: